Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amfenac is a non-steroidal anti-inflammatory drug (NSAID) with antipyretic and analgesic properties. It acts as a potent inhibitor of cyclooxygenase enzymes (COX-1 and COX-2), thereby reducing the synthesis of prostaglandins involved in inflammation, pain, and fever[1][3][6]. Amfenac is the active metabolite of nepafenac, which is used primarily for ocular indications such as pain and inflammation following cataract surgery. Amfenac itself has been studied for use in various inflammatory conditions including rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, gout, headache, dental pain, post-operative pain, menstrual pain (dysmenorrhea), arthralgia (joint pain), muscle pain and fever[5]. Its mechanism involves both reversible inhibition and unique time-dependent irreversible binding to COX enzymes[6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amfenac.